Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

APOLLO PATH, LLC

NPI: 1740675297 · DALLAS, TX 75234 · Clinical Medical Laboratory · NPI assigned 04/01/2015

$797K
Total Medicaid Paid
39,699
Total Claims
21,486
Beneficiaries
30
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialMILCHGRUB, SARA (MEDICAL DIRECTOR)
NPI Enumeration Date04/01/2015

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 2,622 $2K
2019 1,844 $464.88
2020 2,918 $35K
2021 10,461 $237K
2022 12,416 $276K
2023 7,661 $214K
2024 1,777 $34K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 12,220 4,221 $285K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 8,946 2,305 $265K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 9,454 8,293 $108K
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 3,201 1,922 $74K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1,300 872 $48K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 1,194 843 $10K
86769 248 241 $4K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 584 492 $543.22
80061 Lipid panel 349 316 $412.27
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 286 251 $386.43
80053 Comprehensive metabolic panel 569 505 $363.23
84443 Thyroid stimulating hormone (TSH) 391 341 $246.62
83036 Hemoglobin; glycosylated (A1C) 353 312 $195.59
84439 113 100 $114.69
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 127 126 $43.85
80050 General health panel 15 14 $25.76
80048 Basic metabolic panel (calcium, ionized) 37 27 $24.18
82607 72 65 $0.00
86140 13 13 $0.00
82150 13 13 $0.00
83735 75 75 $0.00
84480 13 13 $0.00
82728 13 13 $0.00
84436 14 14 $0.00
82746 13 13 $0.00
82533 13 13 $0.00
83002 13 13 $0.00
84550 34 34 $0.00
84481 13 13 $0.00
84100 13 13 $0.00